slides · global inventory
Title
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 303,780
Current window 222,721-222,750
Pages 10,126
Rows per page 30
Component
222,721-222,750 of 303,780
98
The scatter plot shows a Pearson R of 0.74 for N=5389 data points.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
99
The chart is a dot plot showing affinity (KD) vs edit distance from parent binder. The benchmark is a horizontal dashed line.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
101
The slide illustrates a dual-pathway process leading to a unified AI-driven optimization step.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
102
Includes a Kaplan-Meier survival curve and a biological diagram of TLS.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
103
The slide outlines a proprietary R&D workflow for antibody discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
104
Absci | Investor Presentation Deck | 111 slidesAbsci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
105
The slide illustrates a scientific workflow for target discovery.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
106
The chart shows a dose-dependent increase in absorbance for ABS-301 compared to isotype controls, suggesting binding/inhibition activity.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
107
The slide uses a combination of a horizontal bar chart and a data table to quantify the addressable market.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations 1 hit
110
The slide uses code snippets as decorative background elements.Absci | Investor Presentation Deck | 111 slides · Absci
Conference presentation Investor relations Beat · Satisfaction1 hit
01
The slide features a split design with a white left side containing logos and a dark purple abstract background on the right.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
02
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
04
The slide uses a three-column layout to compare product candidates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Situation & Context1 hit
06
The slide uses a three-column layout to present the company's core technological approaches.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · SolutionLoop · Cost Of Inaction1 hit
07
The chart uses a horizontal bar representation to indicate progress through discovery and IND-enabling stages.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
08
The slide uses a split-screen layout with a photo of a person on the right and branding on the left.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Loop · Quick Win Big Bet1 hit
09
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
10
Includes structural biology visualization, dose-response curves, and a binding affinity table.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
11
Pharmacokinetic study results showing extended half-life for the drug candidate.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations Beat · Evidence & Proof1 hit
12
The slide outlines a standard clinical trial progression for SAD and MAD cohorts, including randomization ratios and participant types.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
13
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
14
Includes PK modeling data comparing human and NHP half-lives and steady-state concentration simulations.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
16
The slide uses a bar chart to show dose-response correlation and a line chart to show pharmacokinetic modeling.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
18
The slide uses two distinct data visualizations: a table for clinical safety metrics and a bar chart for ADA rates.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
19
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
21
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
22
The slide uses a funnel diagram to illustrate the selection process from initial discovery sets to final candidate properties.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
23
The slide uses two distinct chart types: a scatter plot for binding affinity and a dose-response curve for functional inhibition.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
24
Aeglea BioTherapeutics | Investor Presentation Deck | 38 slidesAeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit
25
The slide uses a timeline to frame recent industry activity as validation for the company's asset.Aeglea BioTherapeutics | Investor Presentation Deck | 38 slides · Spyre Therapeutics
Pitch deck Investor relations 1 hit